Nova Eye Medical Limited
Nova Eye Medical Limited (EYE.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Nova Eye Medical Limited (EYE.AX), featuring income statements, balance sheets, and cash flow data.
Nova Eye Medical Limited (EYE.AX) Income Statement & Financial Overview
Explore comprehensive income reports for Nova Eye Medical Limited EYE.AX, broken down by year and quarter.
Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
---|---|---|---|---|
Revenue | $13.19M | $10.14M | $8.63M | $8.39M |
Cost of Revenue | $1.93M | $8.82M | $7.21M | $8.98M |
Gross Profit | $11.26M | $1.32M | $1.43M | -$586000.00 |
Gross Profit Ratio | $0.85 | $0.13 | $0.17 | -$0.07 |
R&D Expenses | $567000.00 | $0.00 | $617000.00 | $0.00 |
SG&A Expenses | $11.48M | $6.93M | $4.09M | $6.65M |
Operating Expenses | $12.05M | $6.93M | $6.06M | $6.42M |
Total Costs & Expenses | $13.97M | $15.74M | $13.27M | $15.39M |
Interest Income | $73000.00 | $51000.00 | $68000.00 | $35000.00 |
Interest Expense | $58000.00 | $12000.00 | $25000.00 | $29000.00 |
Depreciation & Amortization | $1.57M | $1.42M | $1.18M | $1.11M |
EBITDA | -$1.54M | -$4.18M | -$3.36M | -$5.89M |
EBITDA Ratio | -$0.12 | -$0.41 | -$0.40 | -$0.70 |
Operating Income | -$786000.00 | -$5.61M | -$4.63M | -$7.004M |
Operating Income Ratio | -$0.06 | -$0.55 | -$0.54 | -$0.83 |
Other Income/Expenses (Net) | -$2.38M | -$19000.00 | -$6.91M | -$30000.00 |
Income Before Tax | -$3.17M | -$5.63M | -$9.97M | -$7.03M |
Income Before Tax Ratio | -$0.24 | -$0.55 | -$1.15 | -$0.84 |
Income Tax Expense | $0.00 | $0.00 | -$1.28M | -$429000.00 |
Net Income | -$3.17M | -$5.63M | -$8.69M | -$6.61M |
Net Income Ratio | -$0.24 | -$0.55 | -$1.006 | -$0.79 |
EPS | -$0.01 | -$0.03 | -$0.05 | -$0.04 |
Diluted EPS | -$0.01 | -$0.03 | -$0.05 | -$0.04 |
Weighted Avg Shares Outstanding | $217.03M | $195.77M | $169.12M | $149.74M |
Weighted Avg Shares Outstanding (Diluted) | $217.60M | $195.77M | $169.12M | $149.74M |
Over the last four quarters, Nova Eye Medical Limited's revenue moved from $8.39M in Q2 2023 to $13.19M in Q4 2024. Operating income in Q4 2024 was -$786000.00, with a strong operating margin of -6%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Nova Eye Medical Limited remained robust at -$1.54M, reflecting operational efficiency. Net income rose to -$3.17M, with an EPS of -$0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan